Patents by Inventor Lauren Marek

Lauren Marek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGENTS AND METHODS FOR TREATING CBP-DEPENDENT CANCERS
    Publication number: 20250042960
    Abstract: Single chain peptides comprising either a cell penetrating HIV-TAT peptide sequence and a MYB:CBP complex interfering peptide sequence from MYB, or comprising a cell penetrating HIV-TAT peptide sequence, a CBP binding peptide sequence from CREB and a MYB:CBP complex interfering peptide sequence from MYB, are provided for use in preventing MYB:CBP complex formation and downstream events leading to cancer, in particular a leukemia. Both L-amino acid single chain peptides and retro-inverso single chain peptides are provided.
    Type: Application
    Filed: March 12, 2024
    Publication date: February 6, 2025
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: ALEX KENTSIS, KAVITHA RAMASWAMY, LAUREN MAREK
  • Agents and methods for treating CBP-dependent cancers
    Patent number: 11952405
    Abstract: Single chain peptides comprising either a cell penetrating HIV-TAT peptide sequence and a MYB:CBP complex interfering peptide sequence from MYB, or compsiring a cell penetrating HIV-TAT peptide sequence, a CBP binding peptide sequence from CREB and a MYB:CBP complex interfering peptide sequence from MYB, are provided for use in preventing MYB:CBP complex formation and downstream events leading to cancer, in particular a leukemia. Both L-amino acid single chain peptides and retro-inverso single chain peptides are provided.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: April 9, 2024
    Assignee: MEMORAL SLOAN KETTERING CANCER CENTER
    Inventors: Alex Kentsis, Kavitha Ramaswamy, Lauren Marek
  • AGENTS AND METHODS FOR TREATING CBREB BINDING PROTEINS-DEPENDENT CANCERS
    Publication number: 20220144907
    Abstract: Single chain peptides comprising either a cell penetrating HIV-TAT peptide sequence and a MYB:CBP complex interfering peptide sequence from MYB, or comprising a cell penetrating HIV-TAT peptide sequence, a CBP binding peptide sequence from CREB and a MYB:CBP complex interfering peptide sequence from MYB, are provided for use in preventing MYB:CBP complex formation and downstream events leading to cancer, in particular a leukemia. Both L-amino acid single chain peptides and retro-inverso single chain peptides are provided.
    Type: Application
    Filed: November 29, 2021
    Publication date: May 12, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Alex KENTSIS, Kavitha RAMASWAMY, Lauren MAREK
  • Agents and methods for treating CBP-dependent cancers
    Patent number: 11208446
    Abstract: Single chain peptides comprising either a cell penetrating HIV-TAT peptide sequence and a MYB:CBP complex interfering peptide sequence from MYB, or comprising a cell penetrating HIV-TAT peptide sequence, a CBP binding peptide sequence from CREB and a MYB:CBP complex interfering peptide sequence from MYB, are provided for use in preventing MYB:CBP complex formation and downstream events leading to cancer, in particular a leukemia. Both L-amino acid single chain peptides and retro-inverso single chain peptides are provided.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: December 28, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENIER
    Inventors: Alex Kentsis, Kavitha Ramaswamy, Lauren Marek